Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients
| Autor: | Laurie Varlotta, Jeffrey J. Cies |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Pulmonary and Respiratory Medicine
Pediatrics medicine.medical_specialty medicine.diagnostic_test medicine.drug_class business.industry Antibiotics Aminoglycoside Retrospective cohort study medicine.disease Cystic fibrosis Pharmacokinetics Therapeutic drug monitoring Internal medicine Pharmacodynamics Pediatrics Perinatology and Child Health medicine Dosing business |
| Zdroj: | Pediatric Pulmonology. 48:1190-1194 |
| ISSN: | 8755-6863 |
| DOI: | 10.1002/ppul.22745 |
| Popis: | Background Cystic fibrosis (CF) patients are often treated with aminoglycoside (AG) antibiotics during infective pulmonary exacerbations. Achieving pharmacokinetic and pharmacodynamic (PK/PD) targets to improve outcomes and counteract resistance is paramount. Purpose The primary objective was to compare the number of pediatric CF patients achieving AG PK/PD targets when a clinical pharmacist (CP) managed therapeutic drug monitoring (TDM) compared with usual care (UC). Methods A retrospective cohort study was conducted on the records of 40 CF patients that received AGs and ≥2 serum samples between 1/2007 and 5/2009. Chi-square and Student's t-test were used to analyze nominal and continuous variables, respectively. Results Twenty-nine patients with 52 courses of AGs were included the CP group, and 22 patients with 42 courses were included the UC group. Ninety-eight percent of patients in the CP group reached AG PK/PD targets compared with 71% in the UC group, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text